Formycon Ag · XETR:FYB
Formycon — Investor Presentation (May 2026)
18 slides from Formycon's investor presentation, May 19, 2026
Slide 1: Formycon AG – The Biosimilar Experts
Formycon AG The Biosimilar Experts May 2026
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and regulatory approvals or that they will prove to be commercially information which are based on our current expectations and exploitable and/or successful. Formycon AG assumes no certain assumptions. Various known and unknown ris
Slide 3: Skill, mindset and focus are our key success ingredients
Skill, mindset and focus are our key success ingredients Pure Play Biosimilar 200 employees from more Combining high professional Formycon's pipeline Company – established 2012 than 27 different countries. expertise in biopharma- includes three approved in Munich, Germany. ceutical development with
Slide 4: We are acting along a clear mission
We are acting along a clear mission Biosimilars open up enormous opportunities Contributing to ease Improving the financial strains on the patient access to vital world’s healthcare systems medicines 4 Formycon AG The Biosimilar Experts
Slide 5: Four strategic levers for strong competitiveness, value creation and growth
– four strategic levers for strong competitiveness, value creation and growth Geographic 01_ Smart 02_ Excellence 03_ Lean 04_ Diversification Portfolio and Innovation Development A deliberate focus on growing An intelligently designed Excellence in science and Cost efficient fit-for-future market o
Slide 6: Strong outlook for 2026 with key milestones already achieved
– strong Outlook for 2026 with key Milestones already achieved Geographic Smart Portfolio/ Excellence Lean Diversification Progress to Market & Innovation Development FYB201 FYB201 FYB206 Transformation ● Brazil (BIOMM) ● Cimerli® Re-entry in U.S. ● PK equivalence ● FIT4FUTURE: ● Nufymco® (Zydus) de
Slide 7: Huge Biosimilar target opportunities
Huge Biosimilar target opportunities 39 Blockbuster drugs with an expected global sales volume of more than 190 USD billion will lose their exclusivity in the coming years, creating huge opportunities for Biosimilars Year Number of blockbuster drugs losing exclusivity Cumulative global annual peak s
Slide 8: The Biosimilar market develops very dynamically
The Biosimilar market develops very dynamically Global Biosimilar Sales 2016 – 2030 USD billion* 74.0 2015 – 2021 2021 – 2025 RoW CAGR 39% RoW CAGR 16% US CAGR 97% US CAGR 26% Europe CAGR 48% Europe CAGR 8% Biosimilars is the ● ROW fastest growing segment ● US 33.0 ● EUROPE in Pharma. The US market
Slide 9: Diversified portfolio of commercial, late and mid stage programs
Diversified portfolio of commercial, late and mid stage programs Lucentis® 50% Further approvals and * Ophthalmology launches US$ 0.6bn 2022 (Genentech Inc.) owned Stelara® Fully Further Immunology US$ 6.0bn 2025 (Johnson & Johnson) owned launches Eylea®** Out- May 2026 Ophthalmology Launch in US US
Slide 10: Lucentis Biosimilar FYB201 – Strong Presence across the World
Lucentis® Biosimilar FYB201 – Strong Presence across the World FYB201/ranibizumab so far US, DE launched in 24 Countries Epruvy® US Nufymco® UK, EU, Canada MENA Sub-Sahara Brazil Lucentis® is a registered trademark of Genentech Inc.; Ranivisio® is a registered trademark of Bioeq AG; Ongavia® is a re
Slide 11: Stelara Biosimilar FYB202 – first patients treated with Otulfi
Stelara® Biosimilar FYB202 – first Patiens treated with Otulfi® FYB202/ustekinumab launched Global in the US, Europe and Canada DE Fymskina® MENA Sitovab® Stelara® is a registered trademark of Johnson & Johnson Otulfi® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countrie
Slide 12: Eylea Biosimilar FYB203 – launched in EU, US launch Q4 2026
Eylea® Biosimilar FYB203 – launched in EU and will be launched in the US in Q4 2026 FYB203 (aflibercept) is approved in the US, EU, and UK US, Canada AHZANTIVE® EU EU Baiama® Italy MENA Fovlya® APAC LATAM Australia Eylea® is a registered trademark of Regeneron Pharmaceuticals Inc. AHZANTIVE® and Bai
Slide 13: FYB206 – Keytruda Biosimilar candidate in the leading group
FYB206 – Keytruda® Biosimilars candidate in the leading group Achievements and next important Milestones FYB206 ● First commercialization partnership concluded with MS Pharma for the MENA region, for US and Canada with Zydus and for Targeted Reference Indications parts of APAC region with Lotus, fur
Slide 14: FYB208 – Dupixent Biosimilar Candidate successfully achieved TPoS
FYB208 – Dupixent® Biosimilar Candidate successfully achieved TPoS FYB208 Targeted Reference Indications Achievements and next important Milestones Immunology: Moderate to severe atopic dermatitis, severe ● Technical Proof of Similarity (TPoS) achieved in Q3 2025 asthma, chronic rhinosinusitis with
Slide 15: 2026 outlook for Growth
2026 outlook for Growth Guidance Adjusted Working Guidance 2026 Revenue EBITDA 2026 EBITDA Capital ● Revenue: 60 to 70 0 to 10 5 to 15 20 to 30 − Expected significantly above 2025 − Development recharges continue to decrease € million € million € million € million − Growth driven by FYB202 Royalties
Slide 16: Formycon – stable Anchor Investors and increased Liquidity
Formycon – stable Anchor Investors and increased Liquidity Bond: Shareholder Structure **per definition of Deutsche Börse − ISIN / WKN: NO0013586024 / A4DFJH ~ 24 % Santo Holding (Deutschland) GmbH Volume of 70m EUR / Term is 4 years (final payback in July 2029) ~ 13 % Wpart GmbH, Wen.Co Invest GmbH
Slide 17: Fully focused Pure-Play Biosimilar Company
Fully focused Pure-Play Biosimilar Company WE CREATED WE HAVE all ingredients to WE ACT in a highly WE ARE entering the next a strong Platform with successfully fulfill our attractive market stage of the Formycon track record mission Growth Story 17 Formycon AG The Biosimilar Experts
Slide 18: Formycon AG
Formycon AG Formycon AG Fraunhoferstr. 15 82152 Planegg-Martinsried Germany + 49 89 864 667 100 info@formycon.com www.formycon.com 18 Formycon AG The Biosimilar Experts